Jui-Hua Hsieh
Overview
Explore the profile of Jui-Hua Hsieh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
1275
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hsieh J, Nolte S, Hamm J, Wang Z, Roberts G, Schmitt C, et al.
Toxics
. 2023 May;
11(5).
PMID: 37235222
The embryonic zebrafish is a useful vertebrate model for assessing the effects of substances on growth and development. However, cross-laboratory developmental toxicity outcomes can vary and reported developmental defects in...
12.
Lien S, Lin T, Hsieh J, Sung T, Chen J, Hsu K
Comput Biol Med
. 2023 Mar;
156:106722.
PMID: 36878123
Identifying hit compounds is an important step in drug development. Unfortunately, this process continues to be a challenging task. Several machine learning models have been generated to aid in simplifying...
13.
Ireland D, Zhang S, Bochenek V, Hsieh J, Rabeler C, Meyer Z, et al.
Front Toxicol
. 2022 Oct;
4:948455.
PMID: 36267428
Organophosphorus pesticides (OPs) are a chemically diverse class of commonly used insecticides. Epidemiological studies suggest that low dose chronic prenatal and infant exposures can lead to life-long neurological damage and...
14.
Bassan A, Alves V, Amberg A, Anger L, Beilke L, Bender A, et al.
Comput Toxicol
. 2022 Jun;
20.
PMID: 35721273
The kidneys, heart and lungs are vital organ systems evaluated as part of acute or chronic toxicity assessments. New methodologies are being developed to predict these adverse effects based on...
15.
Hsieh J, Behl M, Parham F, Ryan K
Toxicol Sci
. 2022 May;
188(2):198-207.
PMID: 35639960
Compound toxicity data obtained from independent zebrafish laboratories can vary vastly, complicating the use of zebrafish screening for regulatory decisions. Differences in the assay protocol parameters are the primary source...
16.
Bassan A, Alves V, Amberg A, Anger L, Auerbach S, Beilke L, et al.
Comput Toxicol
. 2022 Mar;
20.
PMID: 35340402
Hepatotoxicity is one of the most frequently observed adverse effects resulting from exposure to a xenobiotic. For example, in pharmaceutical research and development it is one of the major reasons...
17.
Hsieh J
Methods Mol Biol
. 2022 Mar;
2474:155-167.
PMID: 35294764
Compound activity identification is the primary goal in high throughput screening (HTS) assays. However, assay artifacts including both systematic (e.g., compound autofluorescence) and nonsystematic (e.g., noise) complicate activity interpretation. In...
18.
Yen S, Chen L, Huang H, HuangFu W, Chen Y, Lin T, et al.
Bioorg Chem
. 2022 Feb;
121:105675.
PMID: 35182882
Fms-like tyrosine kinase 3 (FLT3) is considered a promising therapeutic target for acute myeloid leukemia (AML) in the clinical. However, monotherapy with FLT3 inhibitor is usually accompanied by drug resistance....
19.
Lin T, Chao M, HuangFu W, Tu H, Peng Z, Su C, et al.
Biomed Pharmacother
. 2021 Dec;
146:112580.
PMID: 34968920
The dysregulation of DYRK1A is implicated in many diseases such as cancer, diabetes, and neurodegenerative diseases. Alzheimer's disease is one of the most common neurodegenerative disease and has elevated interest...
20.
Lin T, Yang C, Chou C, Hsu J, Chao M, Sung T, et al.
Biomed Pharmacother
. 2021 Dec;
146:112459.
PMID: 34953394
Chronic inflammation is an underlying cause in a number of diseases. Cyclin-dependent kinase 8 (CDK8) has been implicated as an inflammatory mediator, indicating its potential as an anti-inflammatory target. Herein,...